肺癌是全世界癌症相关死亡的主要原因，即使对于早期诊断的患者来说，预后也很差。目前大多数非小细胞肺癌 (NSCLC) 患者的标准治疗包括一系列化疗、放疗、免疫治疗、靶向治疗和手术切除，具体取决于癌症的阶段和位置。虽然患者的治疗效果确实有所改善，但高度个性化护理的进步仍然有限。然而，通过使用过继细胞转移（ACT）疗法来利用肿瘤浸润淋巴细胞（TIL）的力量越来越令人兴奋。这些 TIL 是天然存在的，可能已经识别肿瘤特异性抗原，并且可以具有直接的抗癌作用。在这篇综述中，我们重点介绍了各种 ACT 的比较，包括 TIL 的简要历史，展示了 TIL 疗法在 NSCLC 中的当前进展和成功，讨论了表观遗传学在 T 细胞扩增中的潜在作用，并强调了该领域面临的挑战和未来方向以个性化方式治疗 NSCLC。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Lung cancer is the leading cause of cancer-related death worldwide, with poor outcomes even for those diagnosed at early stages. Current standard-of-care for most non-small cell lung cancer (NSCLC) patients involves an array of chemotherapy, radiotherapy, immunotherapy, targeted therapy, and surgical resection depending on the stage and location of the cancer. While patient outcomes have certainly improved, advances in highly personalized care remain limited. However, there is growing excitement around harnessing the power of tumor-infiltrating lymphocytes (TILs) through the use of adoptive cell transfer (ACT) therapy. These TILs are naturally occurring, may already recognize tumor-specific antigens, and can have direct anti-cancer effect. In this review, we highlight comparisons of various ACTs, including a brief TIL history, show current advances and successes of TIL therapy in NSCLC, discuss the potential roles for epigenetics in T cell expansion, and highlight challenges and future directions of the field to combat NSCLC in a personalized manner.Copyright © 2024 Elsevier B.V. All rights reserved.